Business and Industry
Benzinga
2021-09-14
Cybin Inc. Likely To Benefit From New Research Touting Psilocybin Mental Health Treatments
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Share:
Related News
Live and Awake in LA
Having attended the surprisingly few SoCal events over the past few years, it was such a welcome pleasure to see familiar faces coming together in LA for 3 days of meaningful conversations centered around healing, community, access, learning, and networking at Psychedelic Awakening 2025 hosted by Psychedelic Institute of Los Angeles.
Read More
Psychedelic Science 2025: Set and (Re)Setting
For its fifth installment, Psychedelic Science 2025 returned to Denver, offering three days of big ideas, heartfelt community, and some noticeable shifts in the psychedelic space. After the usual chaos of delayed flights and travel drama on Tuesday, we shared a collective sigh of relief as we finally arrived at the Colorado Convention Center, a mile high and ready to dive in.
Read More
Mindstate Uses AI to Design “Next-Gen” Psychedelics Combined With 5-MeO-MiPT
Mindstate Design Labs has received approval for a Phase 1 clinical trial to investigate the use of its formulation of 5-MeO-MiPT which it hopes to combine with other drugs to target precise serotonin receptors and create future psychotropic therapies.
Read More